NeoTRIP
Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
- NCT02620280 ↗
- Completed
- Fondazione Michelangelo
- Deep size, estimated: 301+ verified statements
We haven't built an HCP commentary report on NeoTRIP (atezolizumab in early high-risk and locally advanced triple-negative breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 40 newest of 190 indexed sources (Jun 2023 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- What explains differences in atezolizumab outcomes across early TNBC studies
- Whether anthracyclines are needed alongside immunotherapy
- How confidently to interpret the immunotherapy findings
Also discussed: transcriptomic response biomarkers, CD204+ macrophages.
Indexed commentary on NeoTRIP so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 145 posts on X | |
| 32 YouTube videos | |
| 9 podcast episodes | |
| 3 posts on Bluesky | |
| 1 video on X |
The trial
ClinicalTrials.gov- Official title
- Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Invasive Ductal Breast Carcinoma
- Interventions
- Carboplatin; Abraxane; MPDL3280A; Surgery; Anthra
- Arms
- Carbo-abrax, surgery, anthra · Active comparator
- Carbo-abrax-MPDL3280A, surgery, anthra · Experimental
- Enrollment
- 278
- Primary outcomes
- Event Free Survival (EFS)
- Sponsor
- Fondazione Michelangelo
- Start
- Apr 2016
- Primary completion
- Jan 2024
- Results posted
- No
- Registry record
- NCT02620280 · updated Mar 6, 2024
Publications
linked from the registry- Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, Ciruelos EM, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Maffeis I, Valagussa P, Viale G. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. Epub 2022 Feb 17. PubMed 35182721
- Perez-Garcia J, Soberino J, Racca F, Gion M, Stradella A, Cortes J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25. PubMed 32450725